FindTrial
Sign In

Ipilimumab plus nivolumab

DRUG4 trials

Sponsors

Goethe University, Italian Network for Tumor Biotherapy Foundation, Seoul National University Hospital, UNC Lineberger Comprehensive Cancer Center

Conditions

MelanomaMelanoma (Skin Cancer)Melanoma Stage IVMelanoma Stage M1Melanoma Stage Stage IIIBMetastatic Renal Cell CarcinomaMetastatic Renal Cell Carcinoma ( mRCC)Non Small Cell Lung Cancer

Phase 2

Randomized Phase-II Study of Nivolumab Plus Ipilimumab vs. Standard of Care in Untreated and Advanced Non-clear Cell RCC
CompletedNCT03075423
Goethe UniversityMetastatic Renal Cell Carcinoma
Start: 2017-11-01End: 2023-11-23Updated: 2025-09-26
A Study of NIVO Plus IPI and Guadecitabine or NIVO Plus IPI in Melanoma and NSCLC Resistant to Anti-PD1/PDL1
NCT04250246
Italian Network for Tumor Biotherapy FoundationMelanoma, Non Small Cell Lung Cancer
Start: 2020-03-31End: 2025-03-31Target: 184Updated: 2020-01-31
NeoAdjuvant, Spare-Adjuvant (NASA) in Stage IIIB-IV (M1a) Melanoma
Not yet recruitingNCT07740941
UNC Lineberger Comprehensive Cancer CenterMelanoma (Skin Cancer), Melanoma Stage IV, Melanoma Stage M1 +1
Start: 2026-08-05End: 2029-03-01Target: 55Updated: 2026-08-05

Unknown Phase

Immediate Versus Deferred Cytoreductive Nephrectomy With Ipilimumab/Nivolumab in mRCC
Not yet recruitingNCT07233668
Seoul National University HospitalMetastatic Renal Cell Carcinoma ( mRCC)
Start: 2025-12-01End: 2029-02-01Target: 172Updated: 2025-12-03

Related Papers

The phase II NIBIT-ML1 study of nivolumab plus ipilimumab and ASTX727 or nivolumab plus ipilimumab in PD-1 resistant metastatic melanoma: Tumor methylation landscape and correlation with clinical outcomes.
Journal of Clinical Oncology2025-06-04
Ipilimumab/nivolumab versus standard of care in non-clear cell renal cancer: Results of the SUNNIFORECAST trial and potential role of the CPS score and tumor nephrectomy.
Journal of Clinical Oncology2025-05-28
Guadecitabine plus ipilimumab in unresectable melanoma: five-year follow-up and integrated multi-omic analysis in the phase 1b NIBIT-M4 trial.
2023-09-2226 citations
Guadecitabine increases response to combined anti-CTLA-4 and anti-PD-1 treatment in mouse melanoma in vivo by controlling T-cells, myeloid derived suppressor and NK cells
Journal of Experimental & Clinical Cancer Research2023-03-1825 citations
Safety and efficacy of nivolumab plus ipilimumab in patients with advanced non-clear cell renal cell carcinoma: results from the phase 3b/4 CheckMate 920 trial
Journal for ImmunoTherapy of Cancer2022-02-01126 citations
A randomized phase II study of nivolumab plus ipilimumab versus standard of care in previously untreated and advanced non-clear cell renal cell carcinoma (SUNIFORECAST).
Journal of Clinical Oncology2021-05-206 citations
Abstract CT270: A randomized, multi-center, phase II study of nivolumab combined with ipilimumab and guadecitabine or nivolumab combined with ipilimumab in melanoma and NSCLC patients resistant to anti-PD-1/-PD-L1: The NIBIT-ML1 Study
Cancer Research2020-08-154 citations
A randomized phase II study of nivolumab plus ipilimumab versus standard of care in previously untreated and advanced non-clear cell renal cell carcinoma (SUNIFORECAST).
Journal of Clinical Oncology2020-05-2010 citations